Storia in 4 fonti

Merck partner Kelun outlines Phase 3 lung cancer success in China study

Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit could translate to Western patients.

Raccontata da

giovedì 21 maggio 2026·statnews.com
Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with
giovedì 21 maggio 2026·endpoints.news
Merck partner Kelun outlines Phase 3 lung cancer success in China study
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit…

venerdì 22 maggio 2026·

morningstar.com

Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026

venerdì 22 maggio 2026·

fiercepharma.com

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire…

venerdì 22 maggio 2026·

statnews.com

EU and US advisers split over AstraZeneca breast cancer drug

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout

Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows